Lyell Immunopharma, Inc. (LYEL) Return on equity 2021–2025
Lyell Immunopharma, Inc. (LYEL) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-110.6%FY2025 · since FY2021: -26.9% → -110.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -110.6% | -21.0 pp |
| FY2024 | -89.6% | -53.8 pp |
| FY2023 | -35.8% | -13.8 pp |
| FY2022 | -22.0% | +4.9 pp |
| FY2021 | -26.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice